bioAffinity Technologies (bioAffinity Technologies) Short Interest

View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of bioAffinity Technologies's Short Interest

For the Diagnostics & Research subindustry, bioAffinity Technologies's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bioAffinity Technologies's Short Interest Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Short Interest distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's Short Interest falls into.

bioAffinity Technologies (bioAffinity Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAF) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257

Website

https://www.bioaffinitytech.com

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.

Executives

Roby Joyce	director	22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Xavier Trinidad Reveles	officer: Chief Operating Officer	22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Michael Philip Dougherty	officer: Chief Financial Officer	2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232
James Michael Edwards	officer: Chief Financial Officer	30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015
Peter S Knight	director	6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060
Steven Girgenti	director, officer: Executive Chairman	C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Robert A. Anderson	director	70 DOPPLER, IRVINE CA 92618
Gary D Rubin	director, 10 percent owner	2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431
Stuart Diamond	director	498 SEVENTH AVE, NEW YORK NY 10018
Maria Zannes	director, officer: President, CEO	19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256
Harvey Sandler Revocable Trust	10 percent owner	21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180
Mohsin Y Meghji	director	C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016
Vivienne I Rebel	officer: EVP, Chief Sci. & Med. Officer	8922 APACHE TRAIL, SAN ANTONIO TX 78255
Timothy P Zannes	officer: Secretary, EVP, Gen. Counsel	1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106
Nathan M Perlmutter	10 percent owner	28 PARRISH POND LANE, SOUTHAMPTON NY 11968